<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464034</url>
  </required_header>
  <id_info>
    <org_study_id>AMyC 10-MM-01</org_study_id>
    <secondary_id>IST-CAR-521</secondary_id>
    <secondary_id>PO-MM-PI-0034</secondary_id>
    <nct_id>NCT01464034</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Criterium, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Criterium, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated&#xD;
      dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients&#xD;
      with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to&#xD;
      evaluate efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated&#xD;
      dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients&#xD;
      with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to&#xD;
      evaluate efficacy. The study will explore the efficacy of CPD including overall response,&#xD;
      time to progression, progression free survival, and time to next therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Throughout treatment, estimated at 2-12 months per patient</time_frame>
    <description>Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response in Phase II</measure>
    <time_frame>Every 28 days while on treatment (estimated at 2- 12 months per patient)</time_frame>
    <description>Overall Response (SD, MR, PR, VGPR, CR, sCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response in Phase I</measure>
    <time_frame>Every 28 days while on treatment (estimated at 2- 12 months per patient)</time_frame>
    <description>Overall response (SD, MR, PR, VGPR, CR, sCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Every 28 days while on treatment (estimated at 2-12 months per patient)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>throughout follow up (every 2-3 months for 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next therapy</measure>
    <time_frame>throughout follow up (every 2-3 months for 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib, Pomalidomide, Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days</description>
    <arm_group_label>Carfilzomib, Pomalidomide, Dexamethasone</arm_group_label>
    <other_name>PR-171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>PO daily on Days 1-21, every 28 Days</description>
    <arm_group_label>Carfilzomib, Pomalidomide, Dexamethasone</arm_group_label>
    <other_name>CC-4047</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.</description>
    <arm_group_label>Carfilzomib, Pomalidomide, Dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytopathologically or histologically confirmed dx of multiple myeloma&#xD;
&#xD;
          -  Relapsed or refractory to the most recently received therapy.&#xD;
&#xD;
          -  All pts must have received prior lenalidomide therapy and been determined to be&#xD;
             refractory, relapsed, or intolerant.&#xD;
&#xD;
          -  Measurable disease, as indicated by one or more of the following:&#xD;
&#xD;
        Serum M-protein ≥ 0.5 g/dL Urine Bence Jones protein ≥ 200 mg/24 hr Elevated Free Light&#xD;
        Chain as per IMWG criteria, and abnormal ratio&#xD;
&#xD;
          -  Pts must be ≥ 18 years of age&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  ECOG PS of 0-2&#xD;
&#xD;
          -  Adequate hepatic function, with bilirubin &lt; 2 times the upper limit of normal (ULN),&#xD;
             and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3 times ULN&#xD;
&#xD;
          -  Uric acid must be within laboratory normal range&#xD;
&#xD;
          -  CrCl ≥ 50 mL/min&#xD;
&#xD;
          -  Additional Laboratory Requirements ANC ≥1.0 x 109/L Hgb ≥8 g/dL(transfusion permitted)&#xD;
             Platelet count ≥50.0 x 109/L&#xD;
&#xD;
          -  Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony&#xD;
             stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated&#xD;
             G-CSF for at least 2 weeks&#xD;
&#xD;
          -  Pts may receive RBC or platelet transfusions, if clinically indicated, in accordance&#xD;
             with institutional guidelines&#xD;
&#xD;
          -  Screening platelet count should be independent of platelet transfusions for at least 2&#xD;
             weeks.&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines&#xD;
&#xD;
          -  FCBP must agree to ongoing pregnancy testing&#xD;
&#xD;
          -  FCBP must have a negative serum or urine pregnancy test and agree to birth control.&#xD;
&#xD;
          -  Male pts must agree to never have unprotected sexual contact with a female who can&#xD;
             become pregnant and must agree to either completely abstain from sexual contact with&#xD;
             females who are pregnant or are able to become pregnant. The patient must agree to&#xD;
             inform his physician if he has had unprotected sexual contact with a female who can&#xD;
             become pregnant or if he thinks for any reason that his sexual partner may be&#xD;
             pregnant.&#xD;
&#xD;
          -  Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after&#xD;
             completing the study.&#xD;
&#xD;
          -  All pts must be counseled at a minimum of every 28 days about pregnancy precautions&#xD;
             and risks of fetal exposure.&#xD;
&#xD;
          -  Pts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of&#xD;
             prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be&#xD;
             treated with full-dose, low molecular weight heparin, as if to treat deep venous&#xD;
             thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pts with known sensitivity to any immunomodulatory drugs (IMiDs)&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 21 days prior to first dose&#xD;
&#xD;
          -  Exposure to any prior chemotherapy, steroid use, or other myeloma treatment within 14&#xD;
             days prior to first dose. Pts currently on long term steroids do not require any&#xD;
             washout period. in addition, steroid use for spinal cord compression is permitted and&#xD;
             does not require a washout period.&#xD;
&#xD;
          -  Radiation therapy within 14 days prior to first dose&#xD;
&#xD;
          -  Known allergies to carfilzomib or Captisol&#xD;
&#xD;
          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes)&#xD;
&#xD;
          -  Current diagnosis of plasma cell leukemia&#xD;
&#xD;
          -  Waldenström's macroglobulinemia&#xD;
&#xD;
          -  Major surgery within 21 days prior to first dose&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Congestive heart failure (NYHA class III to IV), symptomatic ischemia, conduction&#xD;
             abnormalities uncontrolled by conventional intervention or myocardial infarction in&#xD;
             the previous six months prior to first dose.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Acute active infection requiring systemic antibiotics, antivirals, or antifungals&#xD;
             within 14 days prior to first dose&#xD;
&#xD;
          -  Pts receiving active treatment or intervention for any other malignancy or pts who, at&#xD;
             the Investigator's discretion, may require active treatment or intervention for any&#xD;
             other malignancy within 8 months of starting study treatment.&#xD;
&#xD;
          -  Serious psychiatric or medical conditions that could interfere with treatment&#xD;
&#xD;
          -  Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the&#xD;
             first dose and/or within 14 days before enrollment&#xD;
&#xD;
          -  Contraindication to any of the required concomitant drugs, including proton-pump&#xD;
             inhibitor (e.g. lansoprazole), enteric-coated aspirin or if a history of prior&#xD;
             thrombotic disease, warfarin or low molecular weight heparin&#xD;
&#xD;
          -  Pts in whom the required program of oral and intravenous fluid hydration is&#xD;
             contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment&#xD;
&#xD;
          -  Pts with primary systemic amyloidosis&#xD;
&#xD;
          -  Pts who have received prior treatment with carfilzomib (Phase II only)&#xD;
&#xD;
          -  Pts who have received prior treatment with pomalidomide (Phase II only)&#xD;
&#xD;
          -  Pts who have received prior treatment with both carfilzomib &amp; pomalidomide (Phase I&#xD;
             only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jatin Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMyC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian GM Durie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMyC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The John Theurer Cancer Center @ Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2011</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

